2022
Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
Tuan J, Kayani J, Fisher A, Kotansky B, Dembry L, Datta R. Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e83. PMID: 36483361, PMCID: PMC9726471, DOI: 10.1017/ash.2022.229.Peer-Reviewed Original ResearchDalbavancin administrationOutpatient parenteral antimicrobial therapyDose of dalbavancinMedian antibiotic durationSoft tissue infectionsParenteral antimicrobial therapyAntibiotic durationDeveloped hepatotoxicityClinical cureSeptic arthritisClinical outcomesAntimicrobial therapyPatientsAdministrationDaysEndocarditisArthritisBacteremiaOsteomyelitisHepatotoxicityTherapyDalbavancinInfectionDose
2020
Adverse Events and Healthcare Utilization Associated With Outpatient Parenteral Antimicrobial Therapy Among Older Versus Younger Adults
Brzozowski K, Datta R, Canterino J, Malinis M, Juthani-Mehta M. Adverse Events and Healthcare Utilization Associated With Outpatient Parenteral Antimicrobial Therapy Among Older Versus Younger Adults. Open Forum Infectious Diseases 2020, 7: ofaa358. PMID: 33094112, PMCID: PMC7566523, DOI: 10.1093/ofid/ofaa358.Peer-Reviewed Original ResearchOutpatient parenteral antimicrobial therapyParenteral antimicrobial therapyAdverse eventsAntimicrobial therapyYoung adultsHealthcare utilizationUtilization AssociatedTherapyAdultsVancomycinOxacillin